Submissions from 2021
A Novel Biosignature Identifies DCIS Patients With a Poor Biologic Subtype With an Unacceptably High Rate of Local Recurrence After Breast Conserving Surgery and Radiotherapy, Frank Vicini, Chirag Shah, Pat W. Whitworth, Steven C. Shivers, Fredrik Warnberg, Bruce Mann, and Troy Bremmer
Results of a Multi-Institutional Phase II Clinical Trial for 4DCT-Ventilation Functiona Avoidance Thoracic Radiotherapy., Yevgeniy Vinogradskiy, Richard Castillo, Edward Castillo, Leah Schubert, Bernard L. Jones, Austin M. Faught, Laurie E Gaspar, Jennifer Kwak, Daniel W. Bowles, Timothy Waxweiler, JIngJing M. Dougherty, Dexiang Gao, Craig W. Stevens, Moyed Miften, Brian D Kavanagh, Inga S. Grills, Chad G Rusthoven, and Thomas M. Guerrero
High Dose Rate Brachytherapy as Monotherapy vs. External Beam With HDR Boost in Unfavorable Intermediate Risk Localized Prostate Cancer: A Matched-Pair Analysis, B Willen, D J. Krauss, S R. Nandalur, H Ye, K Marvin, and D Lang
Three-Fraction TRIUMPH-T Brachytherapy for Delivery of APBI Offers Effective Disease Control With Minimal Late Toxicity, Catheryn Yashar, Bruce G Haffty, Peter Chen, Frank Vicini, and Thomas J Quinn
Structure sparsity of the spot optimization in proton arc therapy, Lewei Zhao
Assess the Interplay Effect Based on the Cyclotron Accelerator Proton Therapy System Machine-specific Delivery Sequence Model, Lewei Zhao, Gang Liu, J Shen, A Lee, Di Yan, Rohan Deraniyagala, Craig Stevens, Weili Zheng, Xiaoqiang Li, S Tang, and Xuanfeng Ding
Investigate the Delivery Efficiency and Accuracy of Spot-scanning Proton Arc (SPArc) in Comparison With Conventional IMPT, Automatic Step-and-shoot Multifield IMPT, Lewei Zhao, Gang Liu, Di Yan, Xiaoqiang Li, and Xuanfeng Ding
Assessing the Interplay Effect Based on a Precise Machine-Specific Delivery Sequence and Time for Cyclotron Accelerator Proton Therapy System, Lewei Zhao, G Liu, Weili Zheng, J Shen, A K. Lee, Di Yan, Rohan L. Deraniyagala, Craig W. Stevens, Xiaoqiang Li, S Tang, and Xuanfeng Ding
Breast Irradiation is Well Tolerated in Carriers of a Pathogenic ATM Variant, A H. Zureick, D Zakalik, T S. Rangarajan, T J. Quinn, P Y. Chen, and J T. Dilworth
Submissions from 2020
Dosimteric Impact of Distortion Correction of MR Image Set for Cranial Stereotactic Radiation Treatments, R Sandhu, C Knill, I Grills, P Chinnaiyan, and Z Seymour
Selection of mediastinal lymphoma patients for proton therapy in a prospective multi-institutional registry: Concordance with the ILROG guidelines., YD Tseng, P Mohindra, M Pankuch, LA McGee, CJ Rossi, S Flampouri, C Hajj, JK Molitoris, JHC Chang, HK Tsai, Craig W. Stevens, LR Rosen, CE Vargas, and WF Hartsell
Submissions from 2019
Kidney Injury Molecule-1 Is a Useful Marker to Detect Renal Cell Carcinoma, Oumaima Chaib, Jason Hafron, George D. Wilson, and Ping L. Zhang
Submissions from 2018
Genomic Analysis to Predict Response to Neoadjuvant Chemoradiation Therapy In Rectal Cancer, Andrew Thompson, Thomas J. Quinn, Bryan Thibodeau, Jason Douglas, Claire Peeples, Craig Cousineau, Harry Wasvary, John Robertson, and George D. Wilson